Volume 60, Issue 7 pp. 2094-2101
Systemic Lupus Erythematosus

Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus

Jakub Kwieciński

Jakub Kwieciński

Göteborg University and Sahlgrenska University Hospital, Göteborg, Sweden

Mr. Kwieciński, Mr. Kłak, and Dr. Trysberg contributed equally to this work.

Search for more papers by this author
Marcin Kłak

Marcin Kłak

Göteborg University and Sahlgrenska University Hospital, Göteborg, Sweden

Mr. Kwieciński, Mr. Kłak, and Dr. Trysberg contributed equally to this work.

Search for more papers by this author
Estelle Trysberg

Estelle Trysberg

Karolinska University Hospital, Huddinge, Sweden

Mr. Kwieciński, Mr. Kłak, and Dr. Trysberg contributed equally to this work.

Dr. Trysberg has received consulting fees and speaking fees from Roche (less than $10,000).

Search for more papers by this author
Kaj Blennow

Kaj Blennow

Göteborg University and Sahlgrenska University Hospital, Göteborg, Sweden

Search for more papers by this author
Andrej Tarkowski

Andrej Tarkowski

Göteborg University and Sahlgrenska University Hospital, Göteborg, Sweden

Dr. Tarkowski is deceased.

Search for more papers by this author
Tao Jin

Corresponding Author

Tao Jin

Göteborg University and Sahlgrenska University Hospital, Göteborg, Sweden

Department of Rheumatology and Inflammation Research, Göteborg University, Guldhedsgatan 10, S-413 46 Göteborg, SwedenSearch for more papers by this author
First published: 29 June 2009
Citations: 23

Dr. Trysberg has received consulting fees and speaking fees from Roche (less than $10,000).

Abstract

Objective

A homeostatic imbalance between coagulation and fibrinolysis might occur intrathecally in neuropsychiatric systemic lupus erythematosus (NPSLE). However, there are no published data on levels of fibrinolytic factors in the cerebrospinal fluid (CSF) of patients with NPSLE. The present study was undertaken to assess CSF levels of fibrinolytic molecules, including urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA), D-dimer, and plasminogen activator inhibitor 1 (PAI-1), in SLE patients with clinically verified neuropsychiatric involvement and to compare these levels with those in SLE patients without neuropsychiatric involvement and in healthy subjects.

Methods

Levels of uPA, tPA, and PAI-1 were assessed in CSF from 94 patients with SLE (33 who had NPSLE, 56 who did not have NPSLE, and 5 who were positive for antiphospholipid antibody [not included in the NPSLE or non-NPSLE group]) and from 53 age-matched controls. Patients were evaluated clinically, with magnetic resonance imaging of the brain, analyses of neuronal/glial degradation products in CSF, and neuropsychiatric testing.

Results

In the group of patients with NPSLE, intrathecal PAI-1 levels were significantly elevated compared with levels in SLE patients without overt neuropsychiatric involvement (P < 0.05) and in healthy controls (P < 0.001). In contrast, intrathecal levels of uPA did not differ significantly. Intrathecal levels of PAI-1 correlated significantly with CSF levels of interleukin-6 (IL-6) (r = 0.34, P < 0.001) and IL-8 (r = 0.33, P < 0.001). Importantly, increased PAI-1 and D-dimer levels were observed in SLE patients who had pathologically elevated levels of glial fibrillary acidic protein, neurofilament triplet protein, and tau protein in CSF.

Conclusion

Intrathecal release of PAI-1 is increased in patients with NPSLE. This results in impaired fibrinolysis, which might contribute to neuronal and astrocytic damage in NPSLE.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

click me